NLS Pharmaceutics (NASDAQ:NLSP) Upgraded at Wall Street Zen

NLS Pharmaceutics (NASDAQ:NLSP) was upgraded by equities research analysts at Wall Street Zen to a “sell” rating in a report issued on Saturday.

NLS Pharmaceutics Stock Performance

Shares of NLSP opened at $2.44 on Friday. The company’s fifty day moving average is $2.08 and its 200-day moving average is $1.91. NLS Pharmaceutics has a 12 month low of $1.30 and a 12 month high of $15.59.

About NLS Pharmaceutics

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).